65 completed, 48 unknown, 37 recruiting, 15 terminated. 195 Phase 2, 28 Phase 1, 14 Phase 3.
Follow Purpura: new trials by email Literature Review of Purpura trials Research Report on Purpura
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 36 | 2027-02-08 | 2026-06-25 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1 / Phase 2 | Not yet recruiting | Cullinan Therapeutics Inc. | 72 | 2026-12-01 | 2026-07-31 |
| Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia Zanubrutinib 80mg/d, High dose dexamethasone, Zanubrutinib 160mg/d - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Peking University People's Hospital | 90 | 2026-12-01 | 2026-11-12 |
| TGD001 Treatment in Thrombotic Microangiopathies TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | TargED Biopharmaceuticals B.V. | 70 | 2026-10-25 | 2026-11-12 |
| A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) ianalumab, thrombopoietin receptor agonist (TPO-RA) - Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 164 | 2026-08-04 | 2026-11-06 |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 60 | 2026-07-17 | 2026-10-20 |
| Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP Eltrombopag - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2026-07-10 | 2026-07-07 |
| TPO-RA Plus Baricitinib vs. TPO-RA for ITP Baricitinib, TPO-RA - ITP - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-07-01 | 2026-06-25 |
| Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab Ianalumab - Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-26 | 2026-10-15 | |
| SG301-SC Injection Safety Study in Subjects With Primary ITP Patients low dose group, high dose group, Placebo group - Primary Immune Thrombocytopenia | Phase 2 | Recruiting | Hangzhou Sumgen Biotech Co., Ltd. | 60 | 2026-06-11 | 2026-09-09 |
| Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | Chinese SLE Treatment And Research Group | 164 | 2026-06-07 | 2026-06-18 |
| Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy Orelabrutinib, Romiplostim N01 - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 28 | 2026-04-01 | 2026-02-10 |
| Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) Rituximab, Daratumumab - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 122 | 2026-03-01 | 2026-01-23 |
| Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Rituximab combined with Daratumumab(Anti-CD38 Monoclonal Antibody) - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-03-01 | 2026-01-23 |
| Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Daratumumab(Anti-CD38 Monoclonal Antibody), Rituximab - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 160 | 2026-01-28 | 2026-02-11 |
| Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) Rituximab, Daratumumab - Immune Thrombocytopenia, Treatment | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 160 | 2026-01-20 | 2026-02-11 |
| A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) DZD8586 dose level 1, DZD8586 dose level 2, DZD8586 dose level 3 - Immune Thrombocytopenia (ITP) | Phase 2 | Recruiting | Dizal Pharmaceuticals | 60 | 2026-01-15 | 2026-01-22 |
| Fecal Microbiota Transplantation for Steroid-resistant or Relapsed Immune Thrombocytopenia Fecal microbiota transplantation - Immune Thrombocytopenia (ITP) | Phase 2 | Active not recruiting | Peking University People's Hospital | 42 | 2026-01-10 | 2026-07-29 |
| Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders INCA000585 - Immune Thrombocytopenia | Phase 2 | Recruiting | Incyte Corporation | 56 | 2025-12-29 | 2026-10-30 |
Showing 20 of 195. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (168) · Purpura, Thrombotic Thrombocytopenic (20) · Thrombocytopenia (15) · Purpura, Thrombocytopenic (9) · Anemia, Hemolytic, Autoimmune (7) · Evans Syndrome (5) · Hematologic Diseases (5) · IgA Vasculitis (5) · Anemia, Hemolytic (4) · Blood Platelet Disorders (4) · Lupus Erythematosus, Systemic (4) · Anemia (3) · Arthritis, Rheumatoid (3) · Autoimmune Diseases (3)
Hemic and Lymphatic Diseases (195) · Pathologic Processes (195) · Pathological Conditions, Signs and Symptoms (195) · Signs and Symptoms (195) · Skin Manifestations (195) · Blood Coagulation Disorders (194) · Hemorrhage (194) · Hematologic Diseases (190) · Cytopenia (185) · Thrombotic Microangiopathies (184) · Blood Platelet Disorders (182) · Immune System Diseases (177) · Purpura, Thrombocytopenic (177) · Hemorrhagic Disorders (173)
Dexamethasone (25) · Rituximab (23) · eltrombopag (20) · romiplostim (13) · Danazol (12) · avatrombopag (6) · Immunoglobulins, Intravenous (5) · daratumumab (5) · zanubrutinib (5) · Prednisone (4) · Tretinoin (4) · baricitinib (4) · ianalumab (4) · orelabrutinib (4) · teriflunomide (4)
Peking University People's Hospital (39) · Institute of Hematology & Blood Diseases Hospital, China (24) · Shandong University (9) · Novartis Pharmaceuticals (7) · GlaxoSmithKline (5) · Weill Medical College of Cornell University (5) · Amgen (4) · Assistance Publique - Hôpitaux de Paris (4) · Hospital Universitario Dr. Jose E. Gonzalez (4) · Archemix Corp. (2) · Eisai Inc. (2) · Hamilton Health Sciences Corporation (2) · Keymed Biosciences Co.Ltd (2) · Kyowa Kirin Co., Ltd. (2) · National Heart, Lung, and Blood Institute (NHLBI) (2)
China (84) · United States (54) · United Kingdom (27) · Spain (22) · Germany (18) · Italy (17) · France (16) · Poland (14) · Australia (10) · Canada (10) · Austria (7) · Greece (7) · Czechia (6) · Japan (6) · Mexico (6)
Lei Zhang, MD (12) · Xiao-Hui Zhang, MD (10) · Xiaohui Zhang, MD (6) · David Gomez-Almaguer, MD (3) · James B Bussel, M.D. (3) · Lei Zhang, M.D. (3) · Ming Hou (3) · Xiaohui Zhang (3) · Jamie Y Hur, D.O. (2) · Ming Hou, MD,PhD (2)
PMID 24802773, PMID 23470153, PMID 24802775, PMID 36853224, PMID 12353309, PMID 15389904, PMID 17515510, PMID 18046028, PMID 18463354, PMID 19096013, PMID 19208097, PMID 19231632, PMID 19731307, PMID 19846889, PMID 20058208, PMID 20576011, PMID 20841509, PMID 21636861, PMID 22223819, PMID 22475545, PMID 22915649, PMID 23279219, PMID 23452139, PMID 23492914, PMID 23616916, PMID 23753021, PMID 23829485, PMID 25132654, PMID 25830126, PMID 26504182, PMID 26688484, PMID 26709028, PMID 26863353, PMID 27307776, PMID 27515248, PMID 27643485, PMID 27734464, PMID 28917657, PMID 29270980, PMID 29536526, PMID 30344993, PMID 30472651, PMID 30488420, PMID 30592022, PMID 30957581, PMID 31570488, PMID 31591739, PMID 31821591, PMID 32345372, PMID 33881463
2023 (5), 2018 (4), 2014 (2), 2019 (2), 2016 (1), 2025 (1), U10CA180888 (1), U54AR057319 (1), U54HL112303 (1)